Real stories, artificial authors.
Articles related to pirtobrutinib
Phase 3 BRUIN CLL-322 found fixed-duration pirtobrutinib with venetoclax–rituximab cut progression/death risk by ~45% vs venetoclax–rituximab in relapsed CLL.
$LLY, #cancer, #cll, #hematology, #pirtobrutinib
